Program
dibotatug
Also written as “DR-01” and “Dibotatug (DR-01)”.
Its studies are mostly in Anemia, Aplastic · Alopecia Areata · Leukemia, Large Granular Lymphocytic, led by Dren Bio.
Furthest: phase 2, since Jul 21, 20224 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dren Bio | 43 open or running | phase 2since Jul 21, 2022 | Jul 21, 2022 | Dec 2026phase 2 · NCT05475925 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 21, 2022First study: phase 2 study in Leukemia, Large Granular LymphocyticFirst studyNCT05475925 · 200 planned · United States, Australia, France and more
- Sep 16, 2024Phase 1 study in Alopecia AreataNCT06602232 · 81 enrolled · United States, Australia, New Zealand
- Jan 4, 2025Phase 1 study in Healthy VolunteerNCT06766864 · 32 enrolled · New Zealand
- Jul 14, 2026Phase 2 study in Bone Marrow Failure DisordersNCT07712562 · 60 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Leukemia, Large Granular LymphocyticNCT05475925
- May 2027Primary completion: phase 1 study in Alopecia AreataNCT06602232
- Apr 2029Primary completion: phase 2 study in Bone Marrow Failure DisordersNCT07712562
TargetBeta
KLRD1 →read by rule
“A human non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface receptor and natural killer cell antigen CD94 (killer cell lectin-like receptor D1; KLRD1), ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07712562Bone Marrow Failure Disorders · United States | 2 | Recruiting | Apr 2029 | 60 |
| NCT06766864Healthy Volunteer · New Zealand | 1 | Completed | Aug 27, 2025 | 32 |
| NCT06602232Alopecia Areata · United States, Australia, New Zealand | 1 | Active, not recruiting | May 2027 | 81 |
| NCT05475925Leukemia, Large Granular Lymphocytic · United States, Australia, France and more | 2 | Recruiting | Dec 2026 | 200 |
How it is read
Names in the registry
- “DR-01”, 3 entries
- “Dibotatug (DR-01)”, 1 entry
Conditions, from the studies’ own filings
- Anemia, Aplastic, 1 study
- Alopecia Areata, 1 study
- Leukemia, Large Granular Lymphocytic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.